Vertex Pharmaceuticals VRTX Deferred Foreign Income Tax Expense Benefit
Deferred Foreign Income Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredForeignIncomeTaxExpenseBenefit.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's deferred foreign income tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's deferred foreign income tax expense benefit?
- Vertex Pharmaceuticals (VRTX) reported deferred foreign income tax expense benefit of $9.58M in Q4 2025.
- How has Vertex Pharmaceuticals's deferred foreign income tax expense benefit changed year-over-year?
- Vertex Pharmaceuticals's deferred foreign income tax expense benefit decreased by 72.4% year-over-year, from $34.65M to $9.58M.
- What is the long-term trend for Vertex Pharmaceuticals's deferred foreign income tax expense benefit?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred foreign income tax expense benefit has grown at a -16.8% compound annual growth rate (CAGR), from $55.3M to $38.3M.